Comparison of Results from Two Commercially Available In-House Tissue-Based Comprehensive Genomic Profiling Solutions: Research Use Only AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit and TruSight Oncology 500 Assay.

doi:10.1016/j.jmoldx.2024.08.001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Comparison of Results from Two Commercially Available In-House Tissue-Based Comprehensive Genomic Profiling Solutions: Research Use Only AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit and TruSight Oncology 500 Assay.

The Journal of molecular diagnostics : JMD - 1 Nov 2024

Adams Hans-Peter, Hiemenz Matthew C, Hertel Kay, Fuhlbrück Frederike, Thomas Mara, Oughton James, Sorensen Helle, Schlecht Ulrich, Allen Justin M, Cantone Martina, Osswald Sophie, Gonzalez David, Pikarsky Eli, De Vos Muriel, Schuuring Ed, Wieland Thomas

Abstract excerpt

Increased adoption of personalized medicine has brought comprehensive genomic profiling (CGP) to the forefront. However, differences in assay, bioinformatics, and reporting systems and lack of understanding of their complex interplay are a challenge for implementation and achieving uniformity in CGP testing. Two commercially available, tissue-based, in-house CGP assays were compared, in combination with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computational Biology

Share to DNA Copy Number Variations

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Microsatellite Instability

Share to Neoplasms

Share to Reagent Kits, Diagnostic

Source

Open in PubMed

Identifiers

PMID: 39270817
DOI: 10.1016/j.jmoldx.2024.08.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of Results from Two Commercially Available In-House Tissue-Based Comprehensive Genomic Profiling Solutions: Research Use Only AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit and TruSight Oncology 500 Assay.PMID 39270817Read ↗

Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution.Semantic proximity Read ↗

Development and Clinical Validation of OncCNV: A Pipeline for Comprehensive Genome-Wide Analysis of Oncogene Amplifications, Homozygous Deletions, and Biallelic Inactivation of Tumor Suppressor Genes Using the TruSight Oncology 500 Kit.Semantic proximity Read ↗

TruSight Oncology 500: Enabling Comprehensive Genomic Profiling and Biomarker Reporting with Targeted SequencingSemantic proximity Read ↗

Multicenter In-House Evaluation of an Amplicon-Based Next-Generation Sequencing Panel for Comprehensive Molecular Profiling.Semantic proximity Read ↗

Analytical Validation and Clinical Utilization of the Oncomine Comprehensive Assay Plus Panel for Comprehensive Genomic Profiling in Solid TumorsSemantic proximity Read ↗

A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.Semantic proximity Read ↗

Comparison of next‑generation sequencing quality metrics and concordance in the detection of cancer‑specific molecular alterations between formalin‑fixed paraffin‑embedded and fresh‑frozen samples in comprehensive genomic profiling with the Illumina® TruSight Oncology 500 assaySemantic proximity Read ↗

Comparison of Target Enrichment Platforms for Circulating Tumor DNA Detection.Semantic proximity Read ↗

Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.Semantic proximity Read ↗

Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.Semantic proximity Read ↗

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.Semantic proximity Read ↗

Clinical and Technical Validation of OncoIndx® Assay – A Comprehensive Genome Profiling Assay for Pan-Cancer InvestigationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.